| Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy Q Hu, W Sun, J Wang, H Ruan, X Zhang, Y Ye, S Shen, C Wang, W Lu, ... Nature biomedical engineering 2 (11), 831-840, 2018 | 234 | 2018 |
| Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML RT Swords, S Coutre, MB Maris, JF Zeidner, JM Foran, J Cruz, HP Erba, ... Blood, The Journal of the American Society of Hematology 131 (13), 1415-1424, 2018 | 188 | 2018 |
| Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy HA Knaus, S Berglund, H Hackl, AL Blackford, JF Zeidner, ... JCI insight 3 (21), 2018 | 148 | 2018 |
| Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia JF Zeidner, JE Karp Leukemia research 39 (12), 1312-1318, 2015 | 119 | 2015 |
| Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+ 3) in newly diagnosed acute myeloid … JF Zeidner, MC Foster, AL Blackford, MR Litzow, LE Morris, SA Strickland, ... haematologica 100 (9), 1172, 2015 | 104 | 2015 |
| Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML MA Sekeres, J Watts, A Radinoff, MA Sangerman, M Cerrano, PF Lopez, ... Leukemia 35 (7), 2119-2124, 2021 | 96 | 2021 |
| A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure AM Zeidan, HA Knaus, TM Robinson, AMH Towlerton, EH Warren, ... Clinical Cancer Research 24 (15), 3519-3527, 2018 | 90 | 2018 |
| The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results DA Sallman, AS Asch, S Kambhampati, MM Al Malki, JF Zeidner, ... Blood 136 (Supplement 1), 330, 2020 | 77 | 2020 |
| Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts AM Zeidan, PC Boddu, MM Patnaik, JP Bewersdorf, M Stahl, RK Rampal, ... The Lancet Haematology 7 (8), e601-e612, 2020 | 76 | 2020 |
| Multi-center phase 2 study of pembroluzimab (Pembro) and azacitidine (AZA) in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed (≥ 65 years … I Gojo, RK Stuart, J Webster, A Blackford, JC Varela, J Morrow, AE DeZern, ... Blood 134, 832, 2019 | 58 | 2019 |
| A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms JF Zeidner, JE Karp, AL Blackford, BD Smith, I Gojo, SD Gore, MJ Levis, ... Haematologica 99 (4), 672, 2014 | 58 | 2014 |
| Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach DJ Lee, JF Zeidner Expert opinion on investigational drugs 28 (11), 989-1001, 2019 | 52 | 2019 |
| Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study DA Sallman, MM Al Malki, AS Asch, ES Wang, JG Jurcic, TJ Bradley, ... Journal of Clinical Oncology 41 (15), 2815-2826, 2023 | 51 | 2023 |
| Phase II trial of pembrolizumab after high-dose cytarabine in relapsed/refractory acute myeloid leukemia JF Zeidner, BG Vincent, A Ivanova, D Moore, KP McKinnon, AD Wilkinson, ... Blood cancer discovery 2 (6), 616-629, 2021 | 50 | 2021 |
| Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. NG Daver, P Vyas, S Kambhampati, MM Al Malki, RA Larson, AS Asch, ... Journal of Clinical Oncology 40 (16_suppl), 7020-7020, 2022 | 46 | 2022 |
| AML-196: the first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results D Sallman, A Asch, S Kambhampati, M Al Malki, J Zeidner, W Donnellan, ... Clinical Lymphoma Myeloma and Leukemia 21, S290, 2021 | 37 | 2021 |
| Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+ 3) in newly diagnosed high-risk acute … JF Zeidner, MC Foster, AL Blackford, MR Litzow, LE Morris, SA Strickland, ... Leukemia research 72, 92, 2018 | 37 | 2018 |
| Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia S Rutella, J Vadakekolathu, F Mazziotta, S Reeder, TO Yau, ... The Journal of Clinical Investigation 132 (21), 2022 | 33 | 2022 |
| Final clinical results of a phase II study of high dose cytarabine followed by pembrolizumab in relapsed/refractory AML JF Zeidner, BG Vincent, S Esparza, A Ivanova, DT Moore, MC Foster, ... Blood 134, 831, 2019 | 30 | 2019 |
| Association of acute myeloid leukemia’s most immature phenotype with risk groups and outcomes JM Gerber, JF Zeidner, S Morse, AL Blackford, B Perkins, B Yanagisawa, ... Haematologica 101 (5), 607, 2016 | 29 | 2016 |
